JPX 1188
Alternative Names: JPX-1188Latest Information Update: 11 Apr 2022
At a glance
- Originator Janpix
- Developer Centessa Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action STAT3 transcription factor inhibitors; STAT5 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; T-cell prolymphocytic leukaemia
Most Recent Events
- 04 Apr 2022 Discontinued - Preclinical for Acute myeloid leukaemia in Canada (Parenteral) (Centessa pipeline, April 2022)
- 04 Apr 2022 Discontinued - Preclinical for T-cell prolymphocytic leukaemia in Canada (Parenteral) (Centessa pipeline, April 2022)
- 16 Feb 2021 Janpix has merged with Centessa Pharmaceuticals to form Centessa Pharmaceuticals